Position in NVAX
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$5,273,278
+$1,039,380 QoQ
Shares Held
559,796
+7.6% QoQ
Ownership
0.339%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#29
of 263 holders
Holding Since
Mar 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Edgestream Partners, L.P. holds $89,105,792 across 25 Biotechnology names. NVAX ranks #7 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PCVX |
Vaxcyte, Inc.
|
131,115 | $7,621,714 | |
| 2 | EXEL |
Exelixis, Inc.
|
132,163 | $7,190,988 | |
| 3 | ACAD |
Acadia Pharmaceuticals Inc
|
283,301 | $7,167,515 | |
| 4 | HRMY |
Harmony Biosciences Holdings, Inc.
|
183,501 | $6,681,271 | |
| 5 | INVA |
Innoviva, Inc.
|
269,348 | $6,116,893 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
100,897 | $5,773,326 | |
| 7 | NVAX |
Novavax Inc
This page
|
559,796 | $5,273,278 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
56,715 | $4,496,932 |
All Filings in NVAX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,273,278 | 559,796 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $4,233,898 | 520,135 | Shares | Sole | 2026-05-18 | |
| 2024-09-30 | $1,580,189 | 125,114 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $60,959 | 12,753 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $49,468 | 10,306 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $90,319 | 12,475 | Shares | Sole | 2023-11-15 | |
| 2023-03-31 | $109,085 | 15,741 | Shares | Sole | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||